ProCE Banner Activity

Why I Am Optimistic About Recent Progress in AML

Clinical Thought
Farhad Ravandi, MD, presents his thoughts on the most promising treatment advances in AML and how they might be applied in your practice.

Released: March 22, 2016

Expiration: March 21, 2017

No longer available for credit.

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational donation from

Amgen, Inc.

Faculty Disclosure

Primary Author

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from Amgen, Incyte, Karyopharm, Pfizer, and Sunesis and funds for research support from Amgen, Bristol-Myers Squibb, Incyte, Seattle Genetics, and Sunesis.